Insights on the epigenetic mechanisms underlying pulmonary arterial hypertension

AUTOR(ES)

Luna, R.C.P., de Oliveira, Y., Lisboa, J.V.C., Chaves, T.R., de Araújo, T.A.M., de Sousa, E.E., Miranda Neto, M., Pirola, L., Braga, V.A., de Brito Alves, J.L.

FONTE

Braz J Med Biol Res

DATA DE PUBLICAÇÃO

18/10/2018

RESUMO

Pulmonary arterial hypertension (PAH), characterized by localized increased arterial blood pressure in the lungs, is a slow developing long-term disease that can be fatal. PAH is characterized by inflammation, vascular tone imbalance, pathological pulmonary vascular remodeling, and right-sided heart failure. Current treatments for PAH are palliative and development of new therapies is necessary. Recent and relevant studies have demonstrated that epigenetic processes may exert key influences on the pathogenesis of PAH and may be promising therapeutic targets in the prevention and/or cure of this condition. The aim of the present mini-review is to summarize the occurrence of epigenetic-based mechanisms in the context of PAH physiopathology, focusing on the roles of DNA methylation, histone post-translational modifications and non-coding RNAs. We also discuss the potential of epigenetic-based therapies for PAH.

Documentos Relacionados

• Pathophysiological insights from a case of reversible pulmonary arterial hypertension
• Impact of the Lung Allocation Score on Lung Transplantation for Pulmonary Arterial Hypertension
• SCHISTOSOMAL PULMONARY ARTERIAL HYPERTENSION IN EAST AFRICA
• Diagnosis of pulmonary hypertension from radiographic estimates of pulmonary arterial size.
• Pulmonary Arterial Hypertension in Glycogen Storage Disease Type I